Eli Lilly to buy biotechnology firm Disarm Therapeutics
This article was originally published here
The deal also allows Disarm equity-holders to secure up to $1.225bn in additional future payments for potential development, regulatory and commercial milestones based on the successful development and
The post Eli Lilly to buy biotechnology firm Disarm Therapeutics appeared first on Pharmaceutical Business review.
Leave a Reply
Want to join the discussion?Feel free to contribute!